Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
McKinsey
McKesson
Johnson and Johnson
Express Scripts
Boehringer Ingelheim

Last Updated: December 3, 2022

CLINICAL TRIALS PROFILE FOR LINACLOTIDE


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Linaclotide

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00402337 ↗ Dose-range-finding, Phase 2 Trial of Oral Linaclotide Acetate Administered to Patients With Chronic Constipation Completed Ironwood Pharmaceuticals, Inc. Phase 2 2006-11-01 The primary purpose of this study is to evaluate the efficacy and safety of administration of linaclotide acetate in patients with chronic constipation.
NCT00460811 ↗ Randomized, Double-blind, Dose-range-finding, Phase 2 Study of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation (IBS-C) Completed Ironwood Pharmaceuticals, Inc. Phase 2 2007-04-01 The purpose of this study is to determine the safety, efficacy, and dose response of a range of oral doses of linaclotide administered to patients meeting criteria for IBS-C.
NCT00730015 ↗ Trial of Linaclotide in Patients With Chronic Constipation Completed Forest Laboratories Phase 3 2008-08-01 The objective of this trial is to determine the efficacy and safety of linaclotide administered to patients with chronic constipation (CC). The primary efficacy parameter is the percentage of patients in each dosing group that meet the protocol definition for Complete Spontaneous Bowel Movement (CSBM) Overall Responder.
NCT00730015 ↗ Trial of Linaclotide in Patients With Chronic Constipation Completed Ironwood Pharmaceuticals, Inc. Phase 3 2008-08-01 The objective of this trial is to determine the efficacy and safety of linaclotide administered to patients with chronic constipation (CC). The primary efficacy parameter is the percentage of patients in each dosing group that meet the protocol definition for Complete Spontaneous Bowel Movement (CSBM) Overall Responder.
NCT00730171 ↗ An Open-label, Long-term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation Completed Forest Laboratories Phase 3 2008-09-01 The objective of this study is to assess the long-term safety of linaclotide administered to patients with chronic constipation (CC) or irritable bowel syndrome with constipation (IBS-C).
NCT00730171 ↗ An Open-label, Long-term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation Completed Ironwood Pharmaceuticals, Inc. Phase 3 2008-09-01 The objective of this study is to assess the long-term safety of linaclotide administered to patients with chronic constipation (CC) or irritable bowel syndrome with constipation (IBS-C).
NCT00765882 ↗ Phase III, Randomized, Double-Blind, Placebo-Controlled, Trial of Linaclotide Administered to Patients With Chronic Constipation Completed Ironwood Pharmaceuticals, Inc. Phase 3 2008-09-01 The objective of this trial is to determine the efficacy and safety of linaclotide administered to patients with chronic constipation (CC). The primary efficacy parameter is the percentage of patients in each treatment group that meet the protocol definition for Complete Spontaneous Bowel Movement (CSBM) Overall Responder
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Linaclotide

Condition Name

Condition Name for Linaclotide
Intervention Trials
Irritable Bowel Syndrome With Constipation 9
Chronic Constipation 9
Chronic Idiopathic Constipation 4
Irritable Bowel Syndrome Characterized by Constipation 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Linaclotide
Intervention Trials
Constipation 32
Irritable Bowel Syndrome 19
Syndrome 17
Colorectal Neoplasms 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Linaclotide

Trials by Country

Trials by Country for Linaclotide
Location Trials
United States 600
Canada 22
United Kingdom 10
China 6
Japan 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Linaclotide
Location Trials
Virginia 21
Texas 21
Pennsylvania 21
Georgia 20
Florida 20
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Linaclotide

Clinical Trial Phase

Clinical Trial Phase for Linaclotide
Clinical Trial Phase Trials
Phase 4 5
Phase 3 15
Phase 2 10
[disabled in preview] 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Linaclotide
Clinical Trial Phase Trials
Completed 27
Recruiting 5
Terminated 3
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Linaclotide

Sponsor Name

Sponsor Name for Linaclotide
Sponsor Trials
Ironwood Pharmaceuticals, Inc. 21
Forest Laboratories 15
Astellas Pharma Inc 6
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Linaclotide
Sponsor Trials
Industry 50
Other 38
NIH 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Mallinckrodt
Moodys
Johnson and Johnson
Medtronic
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.